AstraZeneca AZN, -0.93%AZN, +0.45% may resume its halted trial of its COVID-19 vaccine as early as next week, the Financial Times reported, citing people familiar with the matter. The company halted the trial after the discovery of a sick participant, who contracted transverse myelitis, the report said. The trial may see further pauses, the report said, citing a person close to the process.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.